Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPS Challenge PBR28 PET Imaging in Alzheimer's Disease
NCT04057807Phase 1Completed
- Sponsor
- Yale University
- Start
- Apr 2018
- Primary completion
- Jul 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lipopolysaccharide endotoxin in Alzheimer's disease (AD), sponsored by Yale University. Primary endpoint: Microglial Activation Reserve Index. Started Apr 2018; status: completed.
02
Drugs
lipopolysaccharide endotoxin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04057807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04057807.